Figure 2
![Figure 2. Platelet counts and romiplostim doses throughout the 2 years of follow-up of severe chronic ITP patients responding to romiplostim. (A) Median (25th [Q1] and 75th [Q3] percentiles) platelet counts. (B) Romiplostim dose (μg/kg; mean ± SD).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/118/16/10.1182_blood-2011-03-340166/4/zh89991179180002.jpeg?Expires=1736036234&Signature=noLfUYFa8p5HpOOxzU-E58dJNpYOTmmqbp6NHAN4xBccYojSNvPehp~B8AX9g2pj8zy3GWTyAikV8xSjlbptx6XLyVvn0~QwClgNAfnr33YIGMaJBIZPAEoxfEeLaN3fxVtSQkPgkBojVojdk1f~ig0eCPYhrhChqNAjgZ91vJRgHyiFnaJMy-VXq9qb~MHLtAn6StP3ZHzYrHe1z9sCwAVqAoZx1gYHZkEaWKbhFTwCY0qdY9xsonyWnHTBmxxZz2kriA9gc-hOOk7XS9W1PsGpu~vLqcGQuZ~rD-0DLNNv8edAVcBzVb7Ps3-ap9T-WRN7qujxDuuFXy8UF-IYJw__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Platelet counts and romiplostim doses throughout the 2 years of follow-up of severe chronic ITP patients responding to romiplostim. (A) Median (25th [Q1] and 75th [Q3] percentiles) platelet counts. (B) Romiplostim dose (μg/kg; mean ± SD).
Platelet counts and romiplostim doses throughout the 2 years of follow-up of severe chronic ITP patients responding to romiplostim. (A) Median (25th [Q1] and 75th [Q3] percentiles) platelet counts. (B) Romiplostim dose (μg/kg; mean ± SD).
